Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Press releases
September 8, 2021
Eirion Therapeutics Announces Strategic Agreement
As part of the agreement, HTL will build, validate and operate a botulinum manufacturing facility in the US. In the future, HTL Biotechnology expects to apply to the CDC to have the facility certified to manufacture botulinum and later apply to the FDA to have it certified as a GMP plant.
Read more below.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles April 2, 2025François Fournier Featured in Korean Press
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.
-
Articles March 28, 2025HTL Biotechnology at AMWC Monaco 2025
We are excited to share that HTL Biotechnology is present at the AMWC 2025 in Monaco.
-
Articles March 11, 2025HTL Biotechnology at CIBE China
On March 10 to 12, 2025, HTL Biotechnology was proud to be present at CIBE (China International Beauty Expo) in Guangzhou, reaffirming our commitment to the dermatology and beauty industries.